Idelalisib

Chemical formula: C₂₂H₁₈FN₇O  Molecular mass: 415.432 g/mol  PubChem compound: 11625818

Therapeutic indications

Idelalisib is indicated for:

Chronic lymphoid leukemia

Population group: only adults (18 years old or older)

Idelalisib is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

  • who have received at least one prior therapy, or
  • as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Follicular lymphoma (FL)

Population group: only adults (18 years old or older)

Idelalisib is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: ZYDELIG Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈